Skip to main content

Table 1 Prognostic survival analysis results

From: Clinical significance and biological mechanisms of glutathione S-transferase mu gene family in colon adenocarcinoma

Gene Patients
(n = 438)
No. of events (%) MST
(days)
Crude HR
(95% CI)
Crude P Adjusted HR*
(95% CI)
Adjusted P*
GSTM1
 High 219 57 (26.0%) 1849 Ref. 0.018 Ref. 0.006
 Low 219 41 (18.7%) 3042 0.614 (0.410–0.919)   0.559 (0.367–0.849)  
GSTM2
 High 219 59 (26.9%) 2047 Ref. 0.003 Ref. 0.002
 Low 219 39 (17.8%) 2821 0.545 (0.364–0.818)   0.519 (0.342–0.790)  
GSTM3
 High 219 45 (20.5%) 3042 Ref. 0.804 Ref. 0.469
 Low 219 53 (24.3%) 2134 0.804 (0.540–1.197)   0.860 (0.571–1.295)  
GSTM4
 High 219 46 (21.0%) 3042 Ref. 0.387 Ref. 0.729
 Low 219 52 (23.7%) 2134 0.839 (0.563–1.249)   0.930 (0.618–1.400)  
GSTM5
 High 219 53 (24.2%) 2134 Ref. 0.495 Ref. 0.903
 Low 219 45 (20.5%) 2821 1.148 (0.772–1.709)   0.975 (0.647–1.468)  
  1. Notes: *, adjustment for tumor stage
  2. Abbreviations: GSTM, Glutathione S-transferase Mu; MST, median survival time; HR, hazard ratio; CI, confidence interval